natgillin/translations-raw huggingface dataset:
Plant for recycling energy from waste (R), comprising a mill (20) according to any one of the preceding claims and a burner designed for optimum combustion of the Refuse-Derived Fuel produced by the mill (20). 
Pogon za recikliranje energije od otpada (R), obuhvaća mlin (20) sukladno bilo kojem od prethodnih zahtjeva 1 plamenik dizajniran za optimalno sagorijevanje goriva dobivenog iz otpada proizvedenog u mlinu (20).
Venlafaxine hydrochloride belongs to the group of the active ingredients readily soluble in water (0.57 g/ml). 
Venlafaksin hidroklorid pripada skupini aktivnih sastojaka koji su lako topljivi u vodi (0,57 g/ml).
n is an integer of from 0 to 2, which comprises reacting a compound represented by the formula (II): wherein X and m are as defined above, with a compound represented by the formula (VIII): 
(2) reakciju spoja prikazanog formulom (X): (x) gdje su X i m kao što je definirano gore, a R? je alkil, sa spojem formule (XVI): o
After separation of the layers, the aq phase was extracted once with CH2Cl2. 
Poslije razdvajanja slojeva, vodena faza je ekstrahirana jednom sa CH2Ch.
The immune effector cell of claim 19, wherein the immune effector cell is selected from the group consisting of: a T lymphocyte and a natural killer (NK) cell. 
Ex vivo ili in vitro imunološka efektorska stanica u skladu s patentnim zahtjevom 13, naznačena time, što se imunološka efektorska stanica bira iz grupe koja se sastoji od: T limfocita i prirodne stanice ubojice (NK).
The transdermal delivery device of claim 1, wherein the microspheres consist essentially of the opioid antagonist and a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (E-caprolactones), polyanhydrides, albumin, blends and copolymers thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da se mikrosfere u osnovi sastoje od opioidnog antagonista i polimera odabranog iz skupine koja se sastoji od poliestera, polietera, poli(ortoestera), polisaharida, ciklodekstrina, citosana, poli (E-kaprolaktona), polianhidrida, albumina, njihovih mješavina i kopolimera.
A process for preparing a compound according to claim 1 characterised by reacting an intermediate of formula (II) wherein M represents hydrogen or an alkali metal, with a compound of formula (III), in the presence of a base: 
Postupak priprave spoja prema zahtjevu 1, naznačen time da se provodi reakcija međuspojeva formule (II) pri čemu M predstavlja vodik ili alkalni metal, sa spojem formule (III), uz prisutstvo baze: mae zm o
when the second slice segment is not first in the picture, encoding sixth information which indicates whether the second slice segment is a dependent slice segment or not; encoding the second slice segment by using the stored context variable when the sixth information indicates that the second slice segment is a dependent slice segment, wherein the second slice segment is located next to the first slice segment; and generating a bitstream including the information about the maximum coding unit size, the first information, the second information, the fifth information, the sixth information, and the slice segment header including the third information and the fourth information, 
dobivanje, iz toka bitova, druge informacije koja ukazuje je li trenutna LCU posljednja LCU u prvom odsječku segmenta trenutne slike; pohranjivanje varijabli konteksta za trenutnu LCU kada se dekodira posljednji element sintakse trenutne LCU ako prva informacija ukazuje da se ovisni segment odsječka može koristiti u trenutnoj slici i druga informacija ukazuje da je trenutna LCU posljednja LCU u prvom segmentu odsječka trenutne slike;
A crystal of ethyl 3-(4-carboxy-2,6-dichlorophenyl)-2-methylacrylate having a diffraction angle 2θ of a main peak of powder X-ray diffraction of 8.1, 16.3, 19.2, 20.0, 24.8, and 39.0 degrees, wherein the X-ray diffraction measurement conditions are as follows: vacuum tube CuK a-ray, tubular voltage 40kV, tubular current 40mA or 50mA. 
Kristal etil 3-(4-karboksi-2,6-diklorofenil)-2-metilakrilata naznačen time da ima glavni vršak kod difrakcije X- zraka na prahu s kutom difrakcije 20 kod 8.1, 16.3, 19.2, 20.0, 24.8, 1 39.0 stupnjeva, pri čemu su uvjeti mjerenja difrakcije X-zraka kako slijedi: vakuumska cijev CuK a-zraka, napon rendgenske cijevi 40kV, struja rendgenske cijevi 40mA ili SOmA.
Further, providing such runner channels (not being reusable owing to their nature) requires extra material and labor. 
Nadalje, osiguravanje takovih protočnih kanala (koji se zbog njihove naravi više ne mogu ponovno upotrijebiti) zahtjeva poseban materijal i rad.
These values were averaged (means and standard error of the mean) for at least three independent experiments. 
Te vrijednosti su prikazane kao prosječne vrijednosti (srednja vrijednost i standardna pogreška od srednje vrijednosti) za najmanje tri neovisna pokusa.
Most preferred is TWEEN® 20, preferably at a concentration of at or about 0.01 to at or about 10 mg/ml. 
Formulacija prema zahtjevu 9, naznačena time da je Polisorbat 20 prisutan u koncentraciji od 0,01 do 10 mg/ml.
The shell according to claim 1, wherein the discs are 0.58 mm thick, circular and made of steel, and in that the number of discs is within the range 30-60. 
Granata (1) u skladu s patentnim zahtjevom 1, naznačena time da su diskovi (11) debljine 0.58 mm, kružni i izrađeni od čelika, te time da je broj diskova (11) unutar raspona 30 - 60.
According to the invention there is provided an antimicrobial composition substantially consisting of a siliceous sorbent and a medicinal agent immobilized thereon, wherein the siliceous sorbent is pyrogenic silica and the medicinal agent is serrathiopeptidase, both present in the following amounts, % by weight: 
HR P20110107 TI PATENTNI ZAHTJEVI Antimikrobni sastav koji sadrži silikatni sorbent i medicinsko sredstvo imobilizirano na njemu, naznačen time, da silikatni sorbent je pirogeni silicij i medicinsko sredstvo je seratiopeptidaza, oboje prisutno u sljedećim količinama masenih postotaka: pirogeni silicij
The liposome of claim 1, wherein the lipid that is modified by covalent attachment of a polyethylene glycol moiety comprises the PEG structure: wherein n is between 70 and 240, for example wherein n is about 113, and optionally wherein the PEG moiety terminates with an -O methyl group. 
Liposom u skladu s patentnim zahtjevom 1, naznačen time što lipid koji je modificiran kovalentnim pripojenjem polietilen-glikolnog ostatka sadrži PEG strukturu:, gdje je n između 70 i 240, primjerice gdje je n otprilike 113, te gdje PEG ostatak može završavati s -O-metilnom skupinom.
The composition may also have these t and/or hydrodynamic characteristics before the lyophilisation step. 
Sastav također može imati ove T i/ili hidrodinamičke karakteristike prije stupnja liofilizacije.
As such, the nucleotide sequence of the DNA-targeting segment may vary and determines the location within the target DNA that the DNA-targeting RNA and the target DNA will interact. 
Postupak moduliranja polipeptida koji je povezan s ciljanom DNK, naznačen time, da postupak obuhvaća stavljanje u doticaj ciljane DNK s kompleksom koji obuhvaća sljedeće:
A compound of Claim 17 of the Formula: or pharmaceutically acceptable salt thereof. 
Spoj iz patentnog zahtjeva 1 koje ima Formulu:
Another object of the present invention is that of providing a system or plant for carry out the said process, wherein the rolling stands work, without material discontinuity, downstream of the mould and the continuous casting, after an induction furnace, with a minimum distance between outlet from the continuous casting and the first rolling stand. 
Drugi je predmet predstavljenog izuma što omogućuje sustav ili postrojenje za provođenje navedenog postupka, pri čemu valjački stanovi rade, bez prekida kontinuiranosti materijala, nizvodno od kalupa i kontinuiranog lijevanja, nakon indukcijske peći, s najmanjom mogućom udaljenosti između izlaza iz kontinuiranog lijevanja i prvog valjačkog stana.
In one embodiment comprises the immunoassay a detection antibody against digoxygenin conjugated to horseradish peroxidase. In a further embodiment of the method for the immunological determination of an anti-idiotype antibody against an antibody against the amyloid B peptide in a sample the immunoassay comprises the amyloid B peptide conjugated to a solid phase, an antibody against the amyloid B peptide conjugated to digoxygenin as detectable label, and a detection antibody against digoxygenin conjugated to horseradish peroxidase. 
Postupak za imunološko određivanje protutijela za amiloid-B-peptid, naznačen time, da se provodi u uzorku uporabom imunološke analize koja se primjenjuje na protutijelu koje se dobiva iz stanične linije DSM ACC2939, pri čemu imunološka analiza obuhvaća amiloid-f-peptid konjugiran na krutu fazu, anti-idiotipično protutijelo koje je protiv protutijela za amiloid-B-peptid, dobiveno iz stanične linije DSM ACC2939, konjugirano na digoksigenin koji služi kao oznaka koja se može otkrivati, te protutijelo za otkrivanje protiv digoksigenina, konjugirano na peroksidazu.
V is selected from: E is pyrrolidine or piperidine optionally substituted with a hydroxyl group; and R7 is selected from: 
V se bira između: [image]; E je pirolidin ili piperidin, izborno supstituiran s hidroksilnom skupinom; i
The method of claim 1 or 2, wherein the carbodiimide is EDAC (1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide) or a carbodiimide other than EDAC. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je karbodiimid EDAC (1-etil-3-(3-dimetilaminopropil)karbodiimid).
A pharmaceutical composition according to claim 1, having a pH value from 5 to 7. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da mu je pH vrijednost u rasponu od 5 do 7.
if no primitives are generated, storing the video sequence at a first bit-rate, a first frame-rate, and a first resolution; 
ako se ne generiraju podatkovne jedinice, kodiranje video sekvence za dobivanje kodiranog videa koji ima prvu učestalost bita, prvu frekvenciju okvira i prvu rezoluciju;
Intensification of the processes of heat and mass transfer in the well bottom zone in an ultrasonic field, 
Povećanje postupka prijenosa topline i mase u zoni dna izvora u ultrazvučnom polju,
A method of treatment or prevention of a skin condition, comprising the topical application of the composition according to claim 1 onto the skin of a subject afflicted with the skin condition, or at risk of being afflicted with the skin condition. The method of claim 21, wherein the skin condition is skin ageing, elastosis, laxity (sagging), rhytids (wrinkles), skin infection, skin damage, skin burn, pain, and muscle tightness, or combinations thereof. The method of claim 21, wherein the treatment or prevention of the skin condition comprises a cosmetic treatment of the skin to alleviate or prevent the appearance of the skin condition. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bilo kojeg stanja koje se bira iz skupine koju čine starenje kože, elastoza, labavost (mlohavost), nabranost (bore), infekcija kože, oštećenje kože, opeklina kože, bol, te napetost mišića, i njihove kombinacije. Kozmetičko neterapijsko liječenje kože, naznačeno time što se sastoji u primjeni pripravka u skladu s bilo kojim od patentnih zahtjeva 1-8 na koži.
(A white pecipitate was formed). 
(Formirao se bijeli talog).
The latching groove 38 defines a pair of axially spaced, radially inwardly directed protuberances 41 located in use of the jar one above the other. 
Zabravljujući žlijeb 38 definira par ispupčenja 41 aksijalno postavljenih i radijalno usmjerenih prema unutra postavljenih pri korištenju udaraca jedno iznad drugog.
The method according to claim 6, characterized in that the distribution of said adhesive is a distribution of powder of adhesive, or of spots of adhesive of the hot-melt type, having a diameter substantially from 0.1 to 2.0 mm and a density from 50 to 600 spots/cm2. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time, da se navedeno ljepilo nanosi u obliku praškastog ljepila ili se nanose točkice taljivog ljepila promjera u biti 0,1 do 2,0 mm uz gustoću točkica od 50 do 600 točkica na cm2.
The method of claim 1, wherein the therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof is provided at least one of sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed proliferative disorder patient, to maintain remission of an existing patient, or a relapsed/refractory proliferative disease patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli osigurana barem jednom slijedno ili istodobno s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije kod subjekta ili subjektu s relapsiranom ili akutnom mijeloičnom leukemijom (AML).
is hydrogen or alkyl; aryl is a homocycle selected from phenyl, naphthyl, acenaphthyl or tetrahydronaphthyl, each being optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl or mono- or dialkylaminocarbonyl; aryl1 is a homocycle selected from phenyl, naphthyl, acenaphthyl or tetrahydronaphthyl, each being optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, alkylthio, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl, Het or mono- or dialkylaminocarbonyl; 
R'' je vodik ili alkil; aril je homocikal odabran od fenila, naftila, acenaftila ili tetrahidronaftila, koji je svaki proizvoljno supstituiran s 1, 2 ili 3 supstituenata, gdje je svaki supstituent neovisno odabran iz skupa koji čine hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkil, haloalkil, alkiloksi, haloalkiloksi, karboksil, alkiloksikarbonil, aminokarbonil, morfolinil ili mono- ili dialkilaminokarbonil; aril! je homocikal odabran iz skupa koji čine fenil, naftil, acenaftil ili tetrahidronaftil, koji je svaki proizvoljno supstituiran s 1, 2 ili 3 supstituenata, gdje je svaki supstituent neovisno odabran od hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, haloalkila, alkiloksi, alkiltio, haloalkiloksi, karboksila, alkiloksikarbonila, aminokarbonila, morfolinila, Het ili mono- ili dialkilaminokarbonila;
The method of claim 7, wherein: the particle contrast agent composition includes: Crystal Violet and New Methylene Blue in amounts sufficient to result in a ratio of the Crystal Violet to the New Methylene Blue between about 1:1 to about 1:500 under staining conditions; and 
Postupak prema zahtjevu 7, naznačen time da: pripravak sredstva kontrastnih čestica sadrži: Kristal violet i Novo metilensko modrilo u dovoljnoj količini da se dobiju omjer Kristal violet prema Novom metilenskom modrilu između oko 1:1 do oko 1:500 u uvjetima bojenja; i glutaraldehid u dovoljnoj količini da se dobiju koncentracije od ili ispod 0.1% u uvjetima bojenja; i inkubiranje smjese uzorka obuhvaća grijanje smjese uzorka manje od 60 sekundi.
reacting the above compound of formula IIa with 2-bromo-4-fluorophenol to obtain a compound of formula IIIa in the form of diastereomeric mixture (S,R+R,R) 
U _b) reakciju gore navedenog spoja formule Ila sa 2-bromo-4-fluorofenolom, da bi se dobio spoj formule Illa u obliku dijastereoizomerne smjese (S, R+R, R)
Advantages of the invention are summarized as follows: 
Datum podnošenja europske prijave patenta:
The method as claimed in claim 2, characterized in that, if the information is the network-related user data, this information is transmitted to the requesting system. 
Metoda temeljem zahtjeva 2, naznačena time što, ako su podaci korisnički podaci povezani s mrežom, ovi podaci se prenose sustavu koji je postavio zahtjev.
an LC-FR4 comprising the amino acid sequence of SEQ ID NO:20. A humanized monoclonal antibody that binds to STEAP-1, wherein the antibody comprises: 
davanje navedenom pojedincu spomenuto humanizirano monoklonalno protutijelo koje se veže na STEAP-1, pri čemu to protutijelo ima jaki lanac (HC) koji obuhvaća:
The use according to claim 17 for treating an arthritic condition, wherein the administration to said subject of an effective amount of the medicament or the pharmaceutical composition is in combination with one or more therapeutic agent selected in the group of corticoids, TNF blocking agents, anti-interleukins, anti-B lymphocytes, anti-costimulatory molecules, tolerogenic agents, anti-complement proteins, inhibitors of T cell signalling molecules, inhibitors of cell migration, leflunomide, sulfasalazine, hydroxychloroquine, azathioprine, methotrexate, cyclosporine, minocycline, D-penicillamine. 
Lijek ili farmaceutski pripravak prema zahtjevu 15 za liječenje artritičnih stanja, naznačeni time da se efikasna količina lijeka ili farmaceutskog pripravka daje subjektu u kombinaciji s jednim ili više terapijskih agensa iz skupine kortikoida, blokatora TNF-a, anti-interleukina, anti-B limfocita, anti-kostimulacijskih molekula, tolerogenih agensa, anti-komplementarnih proteina, inhibitora signalnih molekula T stanice, inhibitora stanične migracije, leflunomida, sulfasalazina, hidroksiklorokina, azatioprina, metoteksata, ciklosporina, minociklina, D-penicilamina.
A second type of antibody has a binding specificity that is similar or identical to 7D1G, and binds to at least two, three, four, five or six CC chemokines selected from the group consisting CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL14/HCC-1, CCL23/MPIF-1, and CCL18/PARC. 
23/24/25/28/29/30, ili koji se natječe za vezanje na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-18, CCLS5/RANTES, CCLA/HCC-1, i CCLI8/PARC, s antitijelom ili fragmentom koji veže antigen koji sadrži kombinaciju CDR slijedova teškog i lakog lanca SEQ ID NO:
determine an amount of the first substance released by the first cartridge based on said data from the sensor and data from the timer, the timer being configured to measure an amount of time during which the first release device is activated; and estimate a remaining amount of the first substance in the first cartridge based on the determined amount of the first substance released. 
određivanje količine prve tvari oslobođene u prvom spremniku (114) na temelju podataka senzora (240, 291, 292, 293, 294, 295) i podataka iz tajmera (248); i kontroliranje otpuštanja prve tvari na temelju utvrđene količine prve tvari.
An immunoconjugate produced by the method of claim 18. A pharmaceutical composition comprising the immunoconjugate of any one of claims 1 to 15 or 19 and a pharmaceutically acceptable carrier. The immunoconjugate of any one of claims 1 to 15 or 19 for use in the treatment of a disease in an individual in need thereof. 
Farmaceutski pripravak, naznačen time, da obuhvaća imunokonjugat prema bilo kojem od patentnih zahtjeva 1 do 10 ili 14 1 farmaceutski prihvatljivi nosač. Imunokonjugat prema bilo kojem od patentnih zahtjeva 1 do 10 ili 14, naznačen time, da se upotrebljava u liječenju bolesti kod pacijenata kojima je potreban.
The chimeric peptide of any one of claims 1 to 2, wherein the trafficking sequence consists of or comprises the amino acid sequence of SEQ ID NO: 5, 6, 7, 8, 21 or 22. 
Kimerni peptid za uporabu prema bilo kojem zahtjevu 1 do 4, naznačen time da se transportna sekvenca sastoji od ili sadrži sekvencu amino kiseline sa SEQ ID NO: 5, 6, 7,8, 21 ili 22.
The method of claim 1, wherein the immunosuppressant is solubilised or readily soluble, and the composition is a controlled release composition that permits release in the small intestine, ileum and colon. 
Formulacija prema jednom od prethodnih zahtjeva, naznačena time da mini-kapsule imaju profil oslobađanja da bi mogle oslobađati predsolubilizirani ciklosporin u ileumu i/ili tankom crijevu.
The pharmaceutical composition for use according to any one of claims 1 to 6, wherein the composition is a single unit dosage form. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 6, gdje je sastavu pojedinačnom doznom obliku.
The pharmaceutical composition of statement 12, wherein said composition comprises at least one viscosity-increasing agent that reduces or prevents postnasal drip of said composition into the pharynx upon intranasal administration of composition. The pharmaceutical composition of statement 18, wherein said viscosity-increasing agent is selected from the group consisting of a polyvinylpyrrolidone, a cellulose derivative, carrageenan, guar gum, an alginate, a carbomer, a polyethylene glycol, a polyvinyl alcohol and xanthan gum. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni pripravak sadrži najmanje jedno sredstvo za povećavanje viskoznosti, koje se bira iz skupine koju čine polivinilpirolidon, celulozni derivat, kojeg se bira iz skupine koju čine hidroksietilceluloza, karboksimetilceluloza i hipromeloza, karagenan, guar guma, alginat, karbomer, polietilen-glikol, polivinil-alkohol i ksantanska guma, koje smanjuje ili sprječava postnazalno cijeđenje navedenog pripravka u ždrijelo prilikom intranazalne ili okularne primjene pripravka.
The ingredients used in the preparation of tablets containing nebivolol hydrochloride in the present invention by adsorption of drug onto the excipients and subsequent wet granulation method are given below along with the method of preparation of said tablets. 
Sastojci rabljeni za pripremanje tableta koje sadrže nebivolol hidroklorid u ovom izumu putem adsorpcije lijeka na ekscipijente i potonji postupak vlažne granulacije prikazani su ispod zajedno s postupkom pripreme spomenutih tableta.
The compound obtainable by the process of claims 8 or 9, where the co-solvent is selected from the group consisting of toluene, n-butyl chloride, methyl-t-butyl ether, hexane and ethyl acetate and which is crystalline Form II, of 7-[(E)-t-butyloxyiminomethyl]-camptothecin. 
Spoj kojeg se može dobiti postupkom u skladu s patentnim zahtjevima 8 ili 9, naznačen time što se suotapalo bira iz skupine koju čine toluen, 7-butil-klorid, metil-/-butil-eter, heksan i etil-acetat, te što je kristalni Oblik I 7-[(£)-r- butiloksiiminometillkamptotecina.
The pharmaceutical composition according to anyone of claims 3 to 9, wherein said pharmaceutical composition comprises between 1 and 4 mg of granisetron per dosage unit for adults and corresponding doses according to body weight for children and babies. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 3 do 9, naznačen time što spomenuti farmaceutski pripravak sadržava između 1 i 4 mg granisetrona po dozirnoj jedinici za odrasle i odgovarajuće doze prema tjelesnoj masi za djecu i dojenčad.
In still another embodiment, the buffering agent is selected from the group consisting of citrate, glycine, histidine, HEPES, Tris and combinations of these agents. 
Formulacija prema zahtjevu 1, naznačena time da je pufer izabran iz grupe koju čine citrat, glicin, histidin, HEPES, tris i kombinacije ovih sredstava.
A pharmaceutical composition comprising the antibody drug conjugate of any one of claims 1 to 19 in a human unit dose form. 
Farmaceutski sastav koji sadrži konjugat antitijela 1 lijeka prema bilo kojem od zahtjeva 1 do 19 u jediničnom doznom obliku za ljude.
Certain sugars such as fucitol exist exclusively in the open chain form whereas many others (e.g. 
Neki šećeri, kao fucitol, mogu postojati isključivo u otvorenom lančanom obliku, dok mnogi drugi (npr.
The system of claim 7, wherein the layer of deformable material (204) comprises deformable packets filled with a flowable, deformable material or slices of deformable material. 
Sustav prema patentnom zahtjevu 7, naznačen time što sloj materijala koji se može deformirati (204) sadrži pakete koji se mogu deformirati ispunjene s tekućim, materijalom koji se može deformirati ili dijelovima materijala koji se može deformirati.